BGI Refutes Illumina Claims in Letter to Complete Genomics | GenomeWeb

NEW YORK (GenomeWeb News) – A BGI-Shenzhen official has sent a letter to Complete Genomics CEO Cliff Reid refuting claims made by Illumina last week that were intended to cast doubt on BGI's ability to obtain regulatory clearance for their proposed merger and steer Complete Genomics toward a deal with Illumina instead.

BGI already has an agreement in place to acquire Complete Genomics for $3.15 per share, but it has yet to receive US antitrust clearance.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.